Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey
R Naveen,Darpan R Thakare,Masataka Kuwana,John D Pauling,Jessica Day,Mrudula Joshi,Ioannis Parodis,Parikshit Sen,Kshitij Jagtap,Elena Nikiphorou,Sreoshy Saha,Vishwesh Agarwal,Tulika Chatterjee,James B Lilleker,Sinan Kardes,Marcin Milchert,Tamer Gheita,Babur Salim,Tsvetelina Velikova,Abraham Edgar Gracia-Ramos,Ai Lyn Tan,Arvind Nune,Lorenzo Cavagna,Miguel A Saavedra,Samuel Katsuyuki Shinjo,Nelly Ziade,Johannes Knitza,Oliver Distler,Hector Chinoy,COVAD Study Group,Rohit Aggarwal,Latika Gupta,Vikas Agarwal,Ashima Makol,Bhupen Barman,Yogesh Preet Singh,Rajiv Ranjan,Avinash Jain,Sapan C Pandya,Rakesh Kumar Pilania,Aman Sharma,Manesh Manoj M,Vikas Gupta,Chengappa G Kavadichanda,Pradeepta Sekhar Patro,Sajal Ajmani,Sanat Phatak,Rudra Prosad Goswami,Abhra Chandra Chowdhury,Ashish Jacob Mathew,Padnamabha Shenoy,Ajay Asranna,Keerthi Talari Bommakanti,Anuj Shukla,Arunkumar R Pande,Kunal Chandwar,Döndü Üsküdar Cansu,Chris Wincup,Nicoletta Del Papa,Gianluca Sambataro,Atzeni Fabiola,Marcello Govoni,Simone Parisi,Elena Bartoloni Bocci,Gian Domenico Sebastiani,Enrico Fusaro,Marco Sebastiani,Luca Quartuccio,Franco Franceschini,Pier Paolo Sainaghi,Giovanni Orsolini,Rossella De Angelis,Maria Giovanna Danielli,Vincenzo Venerito,Lisa S Traboco,Suryo Anggoro Kusumo Wibowo,Jorge Rojas Serrano,Ignacio García-De La Torre,Erick Adrian Zamora Tehozol,Jesús Loarce-Martos,Sergio Prieto-González,Raquel Aranega Gonzalez,Akira Yoshida,Ran Nakashima,Shinji Sato,Naoki Kimura,Yuko Kaneko,Stylianos Tomaras,Margarita Aleksandrovna Gromova,Or Aharonov,Ihsane Hmamouchi,Leonardo Santos Hoff,Margherita Giannini,François Maurier,Julien Campagne,Alain Meyer,Melinda Nagy-Vincze,Daman Langguth,Vidya Limaye,Merrilee Needham,Nilesh Srivastav,Marie Hudson,Océane Landon-Cardinal,Syahrul Sazliyana Shaharir,Wilmer Gerardo Rojas Zuleta,José António Pereira Silva,João Eurico Fonseca,Olena Zimba
DOI: https://doi.org/10.1007/s00296-023-05310-9
Abstract:The safety profile of COVID-19 vaccines is understudied in patients with systemic sclerosis (SSc). We compared short-term adverse events (AEs) 7 days following vaccination in patients with SSc vs other rheumatic (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HCs). The COVID-19 Vaccination in autoimmune diseases (COVAD) self-reporting e-survey was circulated by a group of > 110 collaborators in 94 countries from March to December 2021. AEs were analyzed between different groups using regression models. Of 10,679 complete respondents [73.8% females, mean age 43 years, 53% Caucasians], 478 had SSc. 83% had completed two vaccine doses, Pfizer-BioNTech (BNT162b2) (51%) was the most common. Minor and major AEs were reported by 81.2% and 3.3% SSc patients, respectively, and did not differ significantly with disease activity or different vaccine types, though with minor symptom differences. Frequencies of AEs were not affected by background immunosuppression, though SSc patients receiving hydroxychloroquine experienced fatigue less commonly (OR 0.4; 95% CI 0.2-0.8). Frequency of AEs and hospitalisations were similar to other AIRDs, nrAIDs, and HC except a higher risk of chills (OR 1.3; 95% CI 1.0-1.7) and fatigue (OR 1.3; 95% CI 1.0-1.6) compared to other AIRDs. COVID-19 vaccines were largely safe and well tolerated in SSc patients in the short term. Background immunosuppression and disease activity did not influence the vaccination-related short-term AEs.